Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition-Reference-Cited by-同舟云学术

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition

Published:2008-09 Issue:13 Volume:44 Page:1922-1930
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bozec Alexandre,Gros François-Xavier,Penault-Llorca Frédérique,Formento Patricia,Cayre Anne,Dental Clélia,Etienne-Grimaldi Marie-Christine,Fischel Jean-Louis,Milano Gérard

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference26 articles.

1. Antiangiogenesis drug design: multiple pathways targeting tumor vasculature;Zhong;Curr Med Chem,2006

2. Antiangiogenesis, anti-VEGF(R) and outlook;Petersen;Recent Results Cancer Res,2007

3. Angiogenesis inhibitors: perspectives for medical, surgical and radiation oncology;Verhoef;Curr Pharm Des,2006

4. Mechanisms of adverse effects of anti-VEGF therapy for cancer;Kamba;Br J Cancer,2007

5. Biological aspects and binding strategies of vascular endothelial growth factor in renal cell carcinoma;Rini;Clin Cancer Res,2007

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-angiogenic and antitumor effects of anlotinib combined with bevacizumab for colorectal cancer;Translational Oncology;2024-03

2. Novel Bifunctional Affibody Molecules with Specific Binding to Both EBV LMP1 and LMP2 for Targeted Therapy of Nasopharyngeal Carcinoma;International Journal of Molecular Sciences;2023-06-14

3. Passive and Active Targeting for Solid Tumors;Environmental Chemistry for a Sustainable World;2022

4. Cediranib, a pan-inhibitor of vascular endothelial growth factor receptors, inhibits proliferation and enhances therapeutic sensitivity in glioblastoma cells;Life Sciences;2021-12

5. Establishment and characterization of a squamous cell carcinoma cell line, designated hZK-1, derived from a metastatic lymph node tumor of the tongue;Human Cell;2017-03-04